Literature DB >> 2597162

Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4.

A M van den Maagdenberg1, P de Knijff, A F Stalenhoef, J A Gevers Leuven, L M Havekes, R R Frants.   

Abstract

The apolipoprotein E3-Leiden variant has been shown to be associated with familial dysbetalipoproteinemia (FD) in a dominant manner (Havekes et al., Hum Genet 1986;73:157-163). Applying the polymerase chain reaction technique, we have cloned and sequenced relevant parts of both APOE alleles of the original proband. In exon 4 of the E*3-Leiden allele a partial gene duplication encompassing 21 nucleotides was found, leading to a tandem repeat of the codons 120-126 or 121-127. Using an E3-Leiden mutation specific oligonucleotide probe, the same mutation was found in two additional independently ascertained FD patients with an E3E3 phenotype based on isoelectric focusing. The E*3-Leiden mutation will be useful in the elucidation of the etiology of dominantly inherited forms of FD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2597162     DOI: 10.1016/s0006-291x(89)80044-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.

Authors:  P J Tacken; F D Beer; L C Vark; L M Havekes; M H Hofker
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

2.  Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

Authors:  P de Knijff; A M van den Maagdenberg; D I Boomsma; A F Stalenhoef; A H Smelt; J J Kastelein; A D Marais; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.

Authors:  P de Knijff; A M van den Maagdenberg; A F Stalenhoef; J A Leuven; P N Demacker; L P Kuyt; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

4.  Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).

Authors:  W A Mann; P Lohse; R E Gregg; R Ronan; J M Hoeg; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.